论文部分内容阅读
目的评价5种拉唑类药物联合其他药物三联治疗幽门螺杆菌(HP)阳性消化性溃疡患者的成本与效果。方法选择160例幽门螺杆菌阳性消化性溃疡患者,将他们随机分为5组,A组35例;B组35例;C组30例;D组30例;E组30例;运用药物经济学成本-效果分析法对5种治疗方案进行分析、评价。结果溃疡愈合成本-效果比(C/E)分别为1.98、1.88、1.69、1.74、0.79;HP根除增量成本-效果比(ΔC/ΔE)分别为5.61、7.39、5.12、12.49;溃疡愈合增量成本-效果比(ΔC/ΔE)分别为4.40、4.60、3.84、6.24。结论综合药物经济学与治疗结果,A、C方案疗效较佳,而C方案更优,值得临床推广。
Objective To evaluate the cost and effect of triple-drug combination of 5 kinds of azole and other drugs in the treatment of patients with Helicobacter pylori (HP) -positive peptic ulcer. Methods A total of 160 patients with H. pylori-positive peptic ulcer were selected and randomly divided into 5 groups: 35 cases in group A, 35 cases in group B, 30 cases in group C, 30 cases in group D and 30 cases in group E, Cost-effectiveness analysis of five kinds of treatment programs were analyzed and evaluated. Results The cost-effectiveness ratio (C / E) of ulcer healing were 1.98,1.88,1.69,1.74 and 0.79, respectively. HP eradication incremental cost-effect ratio (ΔC / ΔE) was 5.61, 7.39, 5.12 and 12.49, The cost-effect ratio (ΔC / ΔE) was 4.40, 4.60, 3.84, 6.24, respectively. Conclusions Comprehensive pharmacoeconomics and treatment results, A, C program better efficacy, and C program is better, worthy of clinical promotion.